论文信息 - Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study - 字舞流文

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study

C. Panizo | R. García‐Muñoz | E. Pérez‐Persona | C. Quero | C. Pérez-López | Abel Domingo-García | Teresa Villaescusa-de-la-Rosa | Ana M Martínez-Castro | José M Arguiñano-Pérez | J. F. Parra-Cuadrado | J. M. Arguiñano-Pérez